REG - Beximco Pharma. - Delay in Results & Temporary Suspension

Beximco PharmaceuticalsAnnouncement

19/12/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251219:nRSS3084Ma&default-theme=true

RNS Number : 3084M  Beximco Pharmaceuticals PLC  19 December 2025

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018. Upon the publication of this
announcement via Regulatory Information Service, this inside information is
now considered to be in the public domain.

 

19 December 2025

 

BEXIMCO PHARMACEUTICALS PLC.

 

Delay in Publication of Annual Results and Temporary Suspension of Trading in
GDRs on AIM

 

Beximco Pharmaceuticals PLC ("the Company"; AIM Symbol: BXP, LEI No.:
213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical
products and active pharmaceutical ingredients, announces that, as it will not
be able to announce its final results and publish its Annual Report and
Accounts, for the year ended 30 June 2025, before 31 December 2025, in
compliance with Rule 19 of the AIM Rules ("AIM Rule 19"), trading in the
Company's GDRs on AIM, will be temporarily suspended from 07.30 a.m. on 2
January 2026.

 

The Board has been unable to approve and publish financial results for the
year ended 30 June 2025, including its audited annual results ("2025 Annual
Results"), as a meeting of the Board of Directors is required. This is not
possible currently because, in line with the Company's previous announcements,
the most recent of which was dated 13 November 2025, Bangladesh Securities and
Exchange Commission ("BSEC")'s proposed appointment of an additional nine
independent non-executive directors to the Company's Board of Directors
remains outstanding in the High Court of Bangladesh ("High Court").

 

The High Court is now in recess and due to a restructuring of the High Court
Benches during 2025, the Company has been informed that its case will now have
to be heard from the start in front of a new High Court Bench. The Company
therefore believes that the High Court's decision on the BSEC Order will not
be forthcoming until January 2026 at the earliest. Following the High Court's
decision, the Company will then be able to approve and publish its annual
results and anticipates that the suspension will be lifted at that time.

 

Shares will continue to trade on the Dhaka Stock Exchange and the Chittagong
Stock Exchange.

 

The Company will continue to make announcements regarding any developments
that need to be disclosed in accordance with its obligations under the AIM
Rules, whilst the temporary suspension is in place.

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com/)  or enquire to:

 

 Beximco Pharma
 Mohammad Ali Nawaz, Chief Financial Officer

 Tel: +880 2 58611001, Ext. 20030

 Mohammad Asad Ullah, FCS

 Executive Director & Company Secretary

 Tel: +880 2 41060531, Ext. 10140

 SPARK Advisory Partners Limited (Nominated Adviser)

 Mark Brady / Andrew Emmott

 Tel: +44 (0)20 3368 3551 / 3555

 SP Angel Corporate Finance LLP (Broker)

 Matthew Johnson

 Tel: +44 (0) 20 3470 0470

 FTI Consulting

 Simon Conway / Sam Purewal

 Tel: +44 (0)20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 6000 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SUSFLFSIFVLALIE



            Copyright 2019 Regulatory News Service, all rights reserved